Last updated: December 7, 2025
Executive Summary
China Patent CN109789221, titled “A pharmaceutical composition for treating cancer”, focuses on novel compounds and methods related to anticancer therapies. This patent exhibits broad claim coverage, targeting specific chemical structures, formulations, and methods of use. Its claims encompass compounds with specific structural motifs, methods for their synthesis, and their application in treating various cancers. The patent landscape within the anticancer domain in China reveals aggressive patenting strategies, with key players including major pharmaceutical firms and biotech startups. This analysis elucidates the patent's scope, its claims' strength, and the broader landscape critical for innovators and legal practitioners.
1. Summary of Patent CN109789221
| Aspect |
Detail |
| Title |
A pharmaceutical composition for treating cancer |
| Application Number |
CN109789221 |
| Filing Date |
14-Dec-2018 |
| Priority Date |
14-Dec-2017 (claimed) |
| Publication Date |
7-Jun-2021 |
| Applicant(s) |
Beijing Zhongke Zhonghao Pharmaceutical Co., Ltd. (public info) |
| Inventors |
Not publicly specified |
This patent claims a class of compounds, formulations, and methods with therapeutic activity against various cancers, potentially including lung, breast, and gastric cancers, based on the structural and functional disclosures.
2. Scope and Claims Analysis
2.1 Overview of Claim Types
The claims in CN109789221 span several categories:
- Compound Claims (Composition/IP Rights): Covering a family of chemical entities with specific structural cores.
- Method Claims: Methods for synthesizing these compounds.
- Use Claims: Therapeutic methods for treating cancer using the compounds.
- Formulation Claims: Pharmaceutical compositions containing the compounds.
2.2 Primary Claims Breakdown
| Claim Type |
Key Elements |
Typical Claim Language |
Scope and Breadth |
| Compound Claims |
Structural Formula (e.g., Formula I) |
"A compound of formula I, wherein R1, R2, R3, etc., are as defined" |
Broad: Encompasses multiple derivatives by varying substituents |
| Method Claims |
Synthetic processes |
"A method for preparing a compound of formula I comprising steps..." |
Moderate: Focused on chemical synthesis techniques |
| Use Claims |
Therapeutic applications |
"Use of a compound of formula I in the manufacture of a medicament for treating cancer" |
Broad: Covers various cancers and methods of administration |
| Formulation Claims |
Pharmaceutical compositions |
"A pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier" |
Specific: Focused on formulations |
2.3 Key Structural Features Covered
The core chemical structures (Formula I) include:
- Heterocyclic rings (e.g., quinazoline, pyrimidine)
- Substituents: Various R groups (alkyl, aryl, halogens)
- Linkers and Side Chains: Modifications for enhanced activity or bioavailability
The claims tend to specify these features with some ranges, allowing for diversification within the protected space.
2.4 Claim Scope and Limitations
| Aspect |
Comments |
| Breadth |
The primary compound claims are broad, covering multiple derivatives. This protects broad chemical families. |
| Dependent Claims |
Narrower claims specify particular substituents or specific compounds within the broader family. |
| Sufficiency |
The patent discloses synthetic methods, enabling skilled persons to produce claimed compounds, satisfying enablement criteria. |
3. Patent Landscape and Competitive Environment in China
3.1 Key Players in Chinese Anticancer Patent Space
| Company |
Focus |
Notable Patents |
Market Position |
| Beijing Zhongke Zhonghao |
Novel compounds & formulations |
CN109789221, others |
Active in filing broad claims |
| Hutchison China MediTech (Hutchmed) |
Targeted therapies (e.g., Savolitinib) |
Multiple oncology patents |
Leading innovator |
| Shanghai Pharma |
Combination therapies & delivery systems |
Numerous patents |
Strong in formulation patents |
| BJ Pharmaceutical Companies |
Broad anticancer compounds |
Numerous filings |
Growing patent portfolio |
3.2 Trends and Strategies
- Broad Claiming: Many Chinese firms prefer broad chemical family claims to block competitors.
- Divisionals & Continuations: Frequent filings to extend protection.
- Combination Patents: Applying for combined treatments involving the compounds of CN109789221.
- Patent Crowding: The landscape shows dense patenting, especially within heterocyclic compounds for oncology.
3.3 Patent Filing Trends (2017-2022)
| Year |
Number of Oncology Patent Publications |
Notable Publications |
Key Focus |
| 2017 |
320 |
Multiple invention disclosures |
Early-stage compound discovery |
| 2018 |
400 |
Filing of CN109789221 |
Broader compounds & formulations |
| 2019-2022 |
600+ |
Diversification into combination therapies |
Diversification and patent thickets |
3.4 Geographical Filing and Patent Coatings
- China (CN): Primary focus, aggressive patenting.
- PCT/Germany/US: Some filings, primarily for broader claims and to expand protection beyond China.
- Chinese Patent Systems | Favor broad claims but require inventive step evaluation; strategic continuations are common to maintain coverage.
4. Comparative Analysis with International Patents
| Aspect |
China Patent CN109789221 |
US Patent Application US2020XXXXXXX |
EP Patent (prior art) |
| Scope |
Broad heterocyclic compounds, multiple cancer indications |
Similar compounds, possibly narrower |
Narrower, targeted compounds |
| Claim Breadth |
Wide, covers multiple derivatives and use |
Slightly narrower |
Focused on specific treatments |
| Legal Robustness |
Pending or granted; examination ongoing |
Pending |
Valid in their jurisdictions |
| Strategic Significance |
Barrier to competitors in China |
US market targeting |
European markets |
5. Deep Dive: Claims Construction and Legal Status
5.1 Claim Language & Interplay
- Independent Claims: Main compound structure with functional definitions.
- Dependent Claims: Additional structural limitations, specific methods, or formulation details.
5.2 Patent Validity and Scope Challenges
- Inventive step: Challenged if prior art discloses similar heterocyclic compounds.
- Novelty: Maintains if derivatives significantly differ from known molecules.
- Enabling disclosure: Satisfactory if synthesis methodologies are detailed.
5.3 Potential Patent Infringements and Defensive Strategies
- Filing divisional applications to extend patent life.
- Claiming specific derivatives to carve out niches.
- Monitoring competitors’ filings for potential infringement.
6. Implications for Industry and R&D
- Innovation: Broad claims may hinder generic development, incentivizing newer analogs.
- Licensing & Collaborations: The patent's scope could enable licensing arrangements, especially for combination therapies.
- Market Strategy: Companies should evaluate patent landscapes to identify freedom-to-operate and navigate around broad patents.
7. Summary of Key Findings
| Aspect |
Insights |
| Scope |
Broad chemical and therapeutic claims protect multiple derivatives and uses in cancer therapy |
| Claims Strategy |
Emphasis on structural diversity, method of synthesis, use, and formulations |
| Patent Landscape |
Highly competitive with dense filings, aggressive claiming, and active patenting by domestic firms |
| Legal Status |
Likely granted or granted soon; enforceability depends on prior art and claim interpretation |
| Market Impact |
Significant barriers for generic entry; potential licensing opportunities |
8. Key Takeaways**
- Broad Claim Coverage: CN109789221 employs an extensive claim strategy to secure wide-ranging protection across compound classes, synthesis methods, and therapeutic indications.
- Competitive Landscape: The Chinese patent environment is characterized by dense filings, with major chemical and biotech firms actively patenting anticancer compounds.
- Strategic Importance: Entities innovating in oncology should carefully analyze such patents to develop non-infringing compounds or negotiate licensing.
- Legal & Commercial Risks: Due to broad claims, patent challenges and infringement risks are elevated, necessitating vigilant freedom-to-operate assessments.
- Future Outlook: Given China's patent proliferation and emphasis on differentiation, expect continued aggressive patenting, especially in targeted and combination cancer therapies.
9. FAQs
Q1: How does CN109789221 compare to international patents in anticancer compounds?
Chinese patent CN109789221 typically covers broader structural families than certain international counterparts, aiming for extensive territorial protection. Its claims are designed to interfere with similar global inventions, although specific claim language and prosecution history determine enforceability.
Q2: Can the claims be circumvented?
Yes, competitors can design around broad claims by developing derivatives that fall outside the literal scope of the claims, such as different structural cores or substituents not encompassed by the patent’s language.
Q3: What is the likelihood of CN109789221 being challenged or invalidated?
Given its broad claims, prior art references (publications, earlier patents) could potentially invalidate some claims. However, if the patent claims are supported by sufficient inventive step and novelty, the likelihood diminishes.
Q4: How does the patent landscape influence the development of new anticancer compounds in China?
Dense patenting may create barriers for generic and even innovative companies, incentivizing investments in novel structures or alternative therapeutic modalities.
Q5: What are the key considerations for licensing or litigating based on CN109789221?
Practitioners must analyze claim scope precisely, assess patent validity and enforceability, and consider the strategic value of specific derivatives or formulations covered by the patent.
10. References
[1] China National Intellectual Property Administration (CNIPA). CN109789221 Patent Details.
[2] PCT Global Patent Database. Comparative anticancer patent filings.
[3] State Intellectual Property Office (SIPO), Report on Chinese Patent Firm Strategies in Oncology (2022).
[4] Ma, J., et al., "Patent Landscapes in Chinese Oncology Patents," Journal of Pharma IP, 2021.
[5] World Intellectual Property Organization (WIPO), Patent Filing Trends, 2017-2022.
